Roche, via its subsidiary Foundation Medicine, agreed to acquire Saga Diagnostics in a deal valued at up to $595 million, expanding Foundation’s molecular residual disease (MRD) footprint. The acquisition is designed to bring Saga’s Pathlight tumor-informed MRD platform into Foundation’s commercial and R&D portfolio. Foundation Medicine says it will integrate Pathlight into existing sequencing workflows and use Roche’s Axelios sequencing and Digital LightCycler PCR platforms to enable broader, decentralized MRD testing globally. Pathlight is currently available in the US for breast and colorectal MRD testing, with Medicare coverage for recurrence monitoring in subtypes of early-stage breast cancer. The transaction underscores how oncology MRD testing remains one of the most investable growth areas in diagnostics, especially as companies race to move MRD from research into wider clinical settings.